MOTS-C

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (sequence MRWQEMGYIFYPRKLR, ~2,122 Da) encoded within the 12S rRNA region of mitochondrial DNA. In preclinical models it activates AMPK (adenosine monophosphate-activated protein kinase) to improve insulin sensitivity and shift substrate use toward fatty-acid oxidation. AMPK is the cell's master energy sensor, and MOTS-c triggers it through an LKB1-dependent phosphorylation cascade [1][4].

JCSG.org supplies research-grade Body Pharm MOTS-c in South Africa.

Three things this article covers: how MOTS-c is encoded in mitochondrial DNA and why that origin matters; the AMPK-dependent mechanism linking MOTS-c to metabolic outcomes; and the regulatory status in South Africa as of 2026.

That local context matters. The IDF Diabetes Atlas 2025 estimates roughly 4.5–5 million South African adults are living with diabetes, a prevalence of 11–13%. SAMRC (South African Medical Research Council) 2023 data indicate about 46% of adults are insufficiently active. Both figures point to a real public-health gap that AMPK-engaging compounds could, in time, help address through research.

Key Takeaways

• MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in mtDNA that activates AMPK to improve insulin sensitivity and metabolic function
• All human efficacy data remain preclinical or early-phase; no large-scale randomised controlled trials have been completed
• MOTS-c is not SAHPRA-registered in South Africa and cannot be supplied for human therapeutic use without Section 21 authorisation
• JCSG.org stocks Body Pharm research-grade MOTS-c
• The AMPK mechanism links MOTS-c mechanistically to metformin but distinguishes it from growth-hormone secretagogues such as CJC-1295

What Is MOTS-c? A Plain-Language Definition

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) with the sequence MRWQEMGYIFYPRKLR and a molecular mass of approximately 2,122 Da. It is encoded within the 12S rRNA region of mitochondrial DNA rather than the nuclear genome [4]. Lee et al. first described it in Cell Metabolism in 2015 [4].

That mitochondrial origin sets MOTS-c apart from the vast majority of signalling peptides in human biology, which are translated from nuclear-encoded mRNAs and processed through the endoplasmic reticulum. Mitochondrial DNA carries only 37 genes. For decades the 12S rRNA locus was assumed to code exclusively for ribosomal RNA. Identifying a small open reading frame within that locus — one that produces a functional peptide with systemic metabolic activity — reframed mitochondria as endocrine-capable organelles that can synthesise and export signalling molecules independent of the nuclear genome.

Why the mtDNA origin matters

Because MOTS-c is transcribed inside the mitochondrion, its expression is sensitive to mitochondrial copy number, heteroplasmy, and the bioenergetic state of the cell. These properties distinguish it mechanistically from nuclear-encoded metabolic regulators. This is why researchers studying related mitochondrial-support compounds, such as NAD+ peptide research, treat MOTS-c as conceptually adjacent. It behaves nothing like a growth hormone secretagogue such as CJC-1295, which acts through pituitary GHRH (growth hormone-releasing hormone) receptors.

How MOTS-c Is Encoded in Mitochondrial DNA

The human mitochondrial genome is a 16,569-base-pair circular, double-stranded DNA molecule encoding 37 genes: 13 protein-coding sequences for oxidative phosphorylation subunits, 22 tRNAs (transfer RNAs), and 2 rRNAs (ribosomal RNAs: 12S and 16S). MOTS-c is translated from a small open reading frame nested inside the 12S rRNA gene, a locus historically annotated as purely structural RNA [1]. Lee et al. identified this short ORF (open reading frame) and showed it produces a functional 16-amino-acid peptide (MRWQEMGYIFYPRKLR, ~2,122 Da) with systemic metabolic activity [1].

That dual-use coding is biologically unusual. The same nucleotide stretch yields both ribosomal RNA and a bioactive peptide, which explains why MOTS-c sat undetected for decades. Mitochondrial DNA also lacks introns and uses a slightly divergent genetic code from the nuclear genome. The ORF is read contiguously without splicing, and translation occurs on mitochondrial ribosomes before the mature peptide is exported to the cytoplasm and bloodstream [1].

The wider mitochondrial-derived peptide family

MOTS-c sits within a small but expanding class of mitochondrial-derived peptides (MDPs) that includes humanin (encoded in 16S rRNA) and the SHLP1–6 series (small humanin-like peptides, also from 16S rRNA) [1]. Conservation of these ORFs across vertebrates is high. Rodent findings, including the Lee et al. 5 mg/kg and 0.5 mg/kg/day intraperitoneal mouse protocols, are considered translationally informative for human physiology despite the absence of South African human trial data.

Why this differs from nuclear-encoded peptides

Nuclear-encoded signalling peptides are transcribed in the nucleus, spliced, and translated on cytosolic ribosomes via the ER (endoplasmic reticulum)–Golgi secretory pathway. MOTS-c bypasses that machinery entirely. This is why it behaves so differently from pituitary-axis agents such as CJC-1295, and why it is grouped conceptually alongside other mitochondrial-support research compounds including NAD+.

The MOTS-c Mechanism: From Mitochondria to AMPK

MOTS-c signals metabolic stress by translocating from mitochondria to the nucleus and activating AMPK, the cell's master energy sensor. AMPK in turn drives glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis [4]. This nuclear translocation step distinguishes MOTS-c from most peptide hormones, which act exclusively through cell-surface receptors and second messengers.

The pathway runs in five discrete stages:

1. Mitochondrial synthesis and export. MOTS-c is translated from the 12S rRNA ORF inside the mitochondrion, then released into the cytoplasm under basal conditions [1].
2. Stress-triggered nuclear translocation. Under glucose restriction, exercise, or other energetic stress, MOTS-c moves into the nucleus. Zheng et al. (2023) report this translocation is itself AMPK-dependent, creating a feed-forward loop [4].
3. Nuclear gene regulation. Once nuclear, MOTS-c modulates stress-response transcriptional networks, including antioxidant and metabolic adaptation genes [4].
4. AMPK activation at Thr172. Zheng et al. (2023) describe phosphorylation of AMPK at Thr172 via an LKB1-dependent route. An AMP/ATP-ratio shift mimics energetic stress and recruits LKB1 to phosphorylate AMPK [4].
5. Downstream metabolic output. Active AMPK increases GLUT4 (glucose transporter type 4)-mediated glucose uptake in skeletal muscle, upregulates fatty-acid β-oxidation, suppresses mTORC1 (mechanistic target of rapamycin complex 1)-driven anabolic signalling, and promotes mitochondrial biogenesis through PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). Gao et al. (2023) extend this axis into bone, where AMPK–PGC-1α signalling underpins MOTS-c's pro-osteogenic effect [4].

Why the metformin comparison matters for South African clinicians

AMPK is also the principal effector of metformin, the first-line Type 2 Diabetes agent on South Africa's Essential Medicines List. MOTS-c reaches the same node by a different route — as an endogenous, exercise-responsive AMPK activator rather than a biguanide — which is why the two compounds produce overlapping metabolic signatures. Lee et al.'s 2015 mouse work showed 0.5 mg/kg/day intraperitoneal MOTS-c for 21 days improved glucose homeostasis and shifted substrate use without altering food intake, a profile pharmacologically adjacent to metformin's [3].

Some clinicians may wonder whether MOTS-c could replace metformin. It cannot. No human efficacy data exist, and metformin remains the evidence-backed standard of care.

Positioning within mitochondrial-support research

The AMPK route groups MOTS-c with other mitochondrial-targeted research compounds such as NAD+. It mechanistically separates MOTS-c from growth-axis peptides like CJC-1295, which act through GHRH receptor signalling rather than cellular energy sensing.

MOTS-c as an Exercise Mimetic: What the Research Shows

An exercise mimetic is a compound that reproduces the cellular and metabolic adaptations of physical activity without the mechanical workload itself. MOTS-c qualifies because it activates AMPK at Thr172 through an LKB1-dependent, energy-stress-like route — the same molecular node engaged by contraction-induced AMP/ATP shifts in working skeletal muscle — triggering the same downstream transcriptional and metabolic cascades [9]. Those downstream effects include GLUT4-mediated glucose uptake, fatty-acid β-oxidation, and PGC-1α-driven mitochondrial biogenesis [9][1].

What the 2023 papers actually show

Zheng et al. (2023) characterise MOTS-c as reproducing key transcriptional signatures of endurance exercise in skeletal muscle. AMPK inhibition partially abolishes those effects, positioning AMPK as the central effector [9]. Gao et al. (2023) extend the picture into musculoskeletal function, reporting that MOTS-c improves muscle performance and bone remodelling via the AMPK–PGC-1α axis. They explicitly frame exercise-induced endogenous MOTS-c as the physiological link between activity and tissue adaptation [3]. Lee et al.'s 0.5 mg/kg/day for 21 days regimen in high-fat-diet mice raised energy expenditure and shifted substrate use toward fat oxidation without altering food intake, consistent with exercise-like metabolic remodelling [6].

Readers concerned that MOTS-c could substitute for physical activity should note that the 2023 reviews are explicit: human translational data remain limited and MOTS-c's exercise-mimetic profile is a preclinical and early-stage human concept [3][1]. No evidence supports MOTS-c as a replacement for structured exercise.

Why this matters for South African research populations

Roughly 47% of South African adults were insufficiently physically active according to WHO (World Health Organization) 2022 estimates. SAMRC analyses place the figure near 46% in 2023 [12][10]. Both data points predate 2024 and should be treated as indicative rather than current. For local researchers studying elderly, obese, or metabolically compromised cohorts who cannot tolerate structured exercise prescriptions, an AMPK-engaging endogenous peptide is a mechanistically coherent investigational tool — not a substitute for activity itself. The 2023 reviews are explicit that human translational data remain limited and that MOTS-c's exercise-mimetic profile is a preclinical and early-stage human concept [3][1].

This positioning links MOTS-c to other mitochondrial-support research compounds such as NAD+ peptide research. It distinguishes MOTS-c mechanistically from growth-axis agents like CJC-1295, which work through GHRH receptor signalling rather than cellular energy sensing.

MOTS-c and Insulin Sensitivity: Key Research Findings

MOTS-c improves insulin sensitivity in preclinical models by activating AMPK in skeletal muscle. This drives GLUT4 translocation, increases glucose uptake, and reduces circulating glucose. GLUT4 is the insulin-responsive glucose transporter, and AMPK-driven translocation bypasses the need for intact insulin signalling [3]. All efficacy data through 2026 derive from rodent studies or small early-phase human work. No large-scale randomised controlled trials in Type 2 Diabetes populations have been completed or published [1][3].

The foundational Lee et al. 2015 Cell Metabolism work established two reference regimens in C57BL/6 mice. The first: 5 mg/kg intraperitoneally once daily for 7 days, which increased skeletal muscle Akt phosphorylation in response to insulin without inducing hypoglycaemia. The second: 0.5 mg/kg/day for 21 days in high-fat-diet mice, which prevented diet-induced obesity and normalised glucose homeostasis without changing food intake [9]. These remain the canonical preclinical dosing benchmarks cited in subsequent mechanistic reviews [1].

The proposed AMPK–GLUT4 pathway

Zheng et al. 2023 attribute MOTS-c's metabolic effects to an energy-stress-like signal. An altered AMP/ATP ratio activates LKB1, which phosphorylates AMPK at Thr172 [3]. Activated AMPK then promotes GLUT4 translocation to the sarcolemma in skeletal muscle, accelerates fatty-acid β-oxidation, and stimulates mitochondrial biogenesis through downstream PGC-1α signalling [3]. Pharmacological AMPK inhibition partially abolishes these benefits in the Zheng et al. models, confirming AMPK as the central effector node rather than a peripheral correlate [3].

Gao et al. 2023, while primarily focused on bone, reinforce that AMPK activation by MOTS-c also reduces insulin resistance in peripheral tissues. It shifts bone-marrow mesenchymal stem cells away from adipogenic differentiation, a phenotype linked to systemic metabolic dysfunction [4].

South African clinical context

The IDF Diabetes Atlas 10th edition (2021) reported approximately 4.2 million South African adults living with diabetes at a prevalence of 11.3% [6]. The IDF Atlas 11th edition (2025) estimates 4.5–5.0 million adults with prevalence of roughly 11–13%. Researchers should verify against the current edition before citing [5]. MOTS-c is not a substitute for first-line therapy such as metformin, and no head-to-head comparative data exist [1]. For researchers mapping mitochondrial-targeted compounds across the metabolic axis, NAD+ peptide research offers a related mechanistic vector. Growth-axis agents like CJC-1295 operate through entirely separate signalling.

Additional Research Areas: Obesity, Muscle and Bone

Gao et al. (2023) consolidate four physiological domains where MOTS-c shows preclinical activity: insulin resistance, obesity, skeletal muscle function, and bone metabolism [5]. The paper had accumulated roughly 30 citations by early 2026 — a modest but growing footprint suggesting genuine academic interest without yet reaching consensus-review status.

Insulin resistance

MOTS-c improves peripheral insulin sensitivity by activating the LKB1–AMPK axis and increasing GLUT4-mediated glucose uptake in skeletal muscle, bypassing insulin-signalling defects common in Type 2 Diabetes [4]. This is the most replicated effect, with rodent data spanning the 5 mg/kg × 7 days and 0.5 mg/kg/day × 21 days regimens from Lee et al. 2015 [2]. Evidence quality: strongest of the four domains, though still preclinical-dominant.

Obesity prevention

In high-fat-diet C57BL/6 mice, 0.5 mg/kg/day MOTS-c for three weeks prevented weight gain without altering food intake. Energy expenditure increased and substrate use shifted toward fatty-acid oxidation. AMPK-driven mitochondrial biogenesis raises oxidative capacity, and hepatic and adipose lipid accumulation fell in parallel [2]. Human translational data remain absent.

Muscle function

Gao et al. describe MOTS-c as an exercise-responsive myokine that enhances mitochondrial biogenesis via AMPK–PGC-1α and supports muscle glucose handling under metabolic stress. PGC-1α is the master regulator of mitochondrial biogenesis and oxidative metabolism [5]. The mechanistic case is plausible, but functional outcomes — strength, endurance, sarcopenia reversal — rest on small animal studies rather than human trials.

Bone metabolism

MOTS-c promotes osteoblast proliferation, mineralisation, and type I collagen synthesis while suppressing osteoclastogenesis through RANKL (receptor activator of nuclear factor kappa-B ligand) downregulation and OPG (osteoprotegerin) upregulation. TGF-β/Smad and AMPK–PGC-1α–ROS (reactive oxygen species) pathways are implicated, as these pathways control osteoblast–osteoclast balance [5]. Gao et al. explicitly flag that in vivo human bone data are lacking [5]. Of the four domains, evidence here is the weakest.

A note on longevity claims

Online marketing frequently extends these mechanisms into anti-ageing and lifespan-extension claims. No human RCT (randomised controlled trial) data support those claims as of 2026, and neither the Gao nor Zheng reviews make any such assertion [4][5]. Researchers comparing mitochondrial-targeted compounds may also review NAD+ peptide research. For a contrasting growth-axis mechanism, see CJC-1295.

MOTS-c Regulatory Status in South Africa (2026)

MOTS-c is not registered as an approved medicine with the South African Health Products Regulatory Authority (SAHPRA) as of 2026 [3]. Searches of the SAHPRA electronic medicines register and complementary medicines listings through 2024–2025 return no dedicated registration, schedule entry, or safety communication for MOTS-c, the sequence MRWQEMGYIFYPRKLR, or the descriptor "mitochondrial-derived peptide" [3]. Any MOTS-c offered locally is unregistered material, not a SAHPRA-approved therapeutic product.

The governing framework is the Medicines and Related Substances Act 101 of 1965, as amended by Act 14 of 2015. This Act establishes SAHPRA's authority over the registration, manufacture, import, and sale of medicines and scheduled substances in South Africa. Under this Act, an unregistered medicine cannot lawfully be supplied for human therapeutic use except through specific exemptions.

Section 21 and the "research chemical" label

Section 21 of the Medicines Act permits SAHPRA to authorise the use of an unregistered medicine in defined circumstances — typically compassionate use for a named patient or supply within an approved clinical trial. A Section 21 application is submitted by a registered medical practitioner and includes a clinical justification. SAHPRA assesses each application against the patient's clinical need and the available evidence. There is no blanket Section 21 cover for peptides as a class.

MOTS-c sold in South Africa carries a "research chemical" or "for research use only" label. That label is a commercial convention, not a regulatory category recognised by the Act. It signals that the material has not been assessed for human safety, efficacy, or quality by SAHPRA. Selling or administering it for human therapeutic use without Section 21 authorisation falls outside the registered medicines framework.

Practical guidance

Anyone considering clinical application should contact SAHPRA directly, engage a registered medical practitioner, and route the request through the Section 21 process where applicable. The peptide regulatory environment is changing and this section should be reviewed at least annually. Readers comparing categories may find the NAD+ peptide research and CJC-1295 overviews useful context.

This article is for informational and research reference purposes only and does not constitute medical or legal advice.

Sourcing MOTS-c in South Africa: JCSG.org Body Pharm

JCSG.org stocks Body Pharm research-grade MOTS-c for South African researchers, with South African delivery. Every batch should be accompanied by a certificate of analysis, and the current price and stock status are shown in the buy box.

Key sourcing checklist before ordering any MOTS-c:

• Request a recent third-party COA (certificate of analysis) confirming purity and sequence identity
• Confirm storage requirements: lyophilised material is held at −20 °C; reconstituted peptide at 2–8 °C
• Verify the supplier's terms of sale clearly state research-use-only supply
• Where any clinical application is contemplated, consult a registered South African medical practitioner and review the Section 21 pathway described above

For mechanistic comparison across mitochondrial and metabolic compounds, see the NAD+ peptide research overview. For contrast with a growth hormone secretagogue, see CJC-1295.

Research Protocols and Dosing: What the Literature Says

No standardised human dosing protocol for MOTS-c exists in peer-reviewed literature as of 2026. Every figure circulated on supplier sites, peptide forums, and telehealth menus is either extrapolated from rodent work or anecdotal. Human pharmacokinetics and optimal dosing remain undefined, so none of it should be treated as clinical guidance.

The canonical preclinical doses come from Lee et al. 2015, who reported two intraperitoneal regimens in mice: 5 mg/kg once daily for 7 days in C57BL/6 animals to improve whole-body insulin sensitivity, and 0.5 mg/kg/day for 21 days in high-fat-diet mice to prevent weight gain and shift substrate use toward carbohydrate and fatty-acid oxidation [1][2]. Gao et al. 2023 reproduced AMPK- and TGF-β/Smad-linked osteogenic effects using comparable intraperitoneal dosing in rodent bone metabolism models, again without translating to a human equivalent [10]. Direct mg/kg conversion from mouse to human is not pharmacologically valid for a peptide of this class. Peptide absorption, distribution, and clearance differ substantially between species, and the Alzheimer's Drug Discovery Foundation profile explicitly flags that human dosing remains undefined outside small phase 1 trials of analogues such as CB4211 [1].

Handling in a research setting

In research environments MOTS-c is typically administered by subcutaneous injection after reconstitution in sterile water for injection, 0.9% saline, or bacteriostatic saline. Lyophilised material is held at −20 °C (−80 °C for storage beyond several months). Reconstituted peptide is kept at 2–8 °C for one to two weeks, or aliquoted and re-frozen to avoid freeze–thaw cycles [11][12].

Any contemplated clinical use should be routed through a registered medical practitioner under the Section 21 pathway described earlier. For mechanistic contrast across the category, see the NAD+ peptide research overview and the CJC-1295 profile.

How MOTS-c Compares to Related Mitochondrial Peptides

MOTS-c sits within a small family of mitochondrial-derived peptides (MDPs) encoded inside mtDNA, alongside humanin and the six SHLP peptides (SHLP1–6). Humanin, identified by Hashimoto and colleagues in 2001, was the first MDP characterised and is studied predominantly for neuroprotection and apoptosis suppression in Alzheimer's and ischaemia models. MOTS-c, by contrast, is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR, ~2.1 kDa) encoded within the 12S rRNA region whose primary signalling node is AMPK activation via LKB1 and Thr172 phosphorylation, driving glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis [3][8]. The SHLPs, encoded within the 16S rRNA region, show mixed metabolic and cytoprotective effects but remain less well characterised than either humanin or MOTS-c.

Adjacent research compounds

Two comparators are worth flagging for South African researchers planning mechanistic studies. NAD+ acts upstream of sirtuin-mediated mitochondrial regulation rather than through AMPK directly, making it mechanistically complementary rather than redundant. CJC-1295 is a growth hormone-releasing hormone analogue with no mitochondrial signalling role; any overlap with MOTS-c is downstream and indirect, through body composition changes.

Stacking mitochondrial-support compounds is an active preclinical research question. No human combination protocol involving MOTS-c has been validated in peer-reviewed trials as of 2026 [3][8].

Current Research Gaps and What to Watch in 2026–2027

The MOTS-c evidence base in 2026 has no completed large-scale human randomised controlled trials. Five gaps materially constrain clinical interpretation. Researchers and informed consumers in South Africa should weigh these limitations against the mechanistic enthusiasm in supplier marketing.

• No human RCTs at scale. Published human data remain limited to small physiological and observational studies. The Zheng et al. 2023 AMPK review and Gao et al. 2023 bone-metabolism paper still represent the review-level evidence ceiling [14][11].
• Unknown optimal human dose and route. The canonical 0.5 mg/kg/day and 5 mg/kg intraperitoneal mouse regimens from Lee et al. 2015 have no validated human equivalent. Subcutaneous versus intramuscular pharmacokinetics in humans are uncharacterised [5].
• Long-term safety profile not established. No multi-year human safety data exist. Research-use-only framing from suppliers reflects this limitation.
• Species translation unconfirmed. Most mechanistic data, including the AMPK–PGC-1α–ROS axis findings on osteoclasts, derive from murine models or in vitro work [11].
• Nuclear translocation poorly characterised in humans. Zheng et al. 2023 describe AMPK-dependent nuclear localisation modulating stress-response genes. The human cell-line work needed to map this fully is still thin [14].

South African contributions could close several of these gaps. The University of Cape Town's Exercise Science and Sports Medicine unit is well placed to run exercise–MOTS-c interaction studies. The SAMRC has the infrastructure to host metabolic-endpoint trials relevant to the 11–13% adult diabetes prevalence recorded in the IDF Diabetes Atlas 2025 [6][8]. This section will be updated as 2026–2027 human trial registrations and PMC-indexed outcomes appear.

Frequently Asked Questions About MOTS-c in South Africa

MOTS-c occupies an unusual regulatory and commercial position in South Africa: not registered as a medicine, but openly sold as research material. The answers below summarise the practical implications.